Avience Biomedicals IPO：价格区间、GMP 及关键投资详情

总部位于诺伊达（Noida）的分子诊断制造商 Avience Biomedicals 将于本周四推出备受期待的 IPO。由于灰色市场反映出强劲的上市前需求，投资者正密切关注这一 SME 发行项目，该公司旨在通过此次募资为其下一阶段的制造扩张提供资金。

IPO 定价、时间表及灰色市场热度

Avience Biomedicals IPO 的定价区间为每股 196 卢比至 208 卢比。认购窗口将于本周四开启，并持续至 6 月 22 日。投资者可以预期配售流程将于 6 月 23 日完成，公司计划于 6 月 25 日在 NSE SME 平台上市。

市场情绪表现看涨，因为在开盘前，灰色市场溢价 (GMP) 约为 36%。这意味着非官方市场价格约为 283 卢比，较价格区间上限溢价约 75 卢比。如此强劲的 GMP 预示着投资者兴趣浓厚，使其区别于本周表现平淡的其他 SME 发行项目。

发行结构与分配详情

总发行规模为 3.024 亿卢比 (Rs 30.24 crore)，全部由 1,453,800 股的新股发行组成。值得注意的是，本次发行不包含现有股东减持 (OFS) 部分，从而确保所有募集资金都将用于公司的增长计划。在总发行量中，为做市商 Asnani Stock Broker 预留 82,200 股后，剩余 1,371,600 股面向公众发行。

分配结构倾向于机构参与：

对于零售投资者，每手 (lot size) 固定为 600 股，按价格区间上限计算，最低投资额为 124,800 卢比。高净值人士 (HNI) 必须申请至少 3 手（1,800 股），总计约 374,400 卢比。

商业模式与财务表现

Avience Biomedicals is an ISO-certified manufacturer specializing in molecular diagnostic solutions, biotechnology, and genomics. Their product portfolio is diverse, ranging from rapid test kits for dengue and malaria to biochemistry analysers and medical devices like oxygen concentrators. The company operates a B2B and B2G model, serving hospitals, pathology labs, and research centers both in India and internationally.

The company has demonstrated significant financial momentum. Revenue surged from Rs 24.37 crore in FY24 to Rs 45.97 crore in FY25. Even more impressive is the bottom-line growth, with Profit After Tax (PAT) jumping from Rs 2.14 crore in FY24 to Rs 7.23 crore in FY25. For the ten months ending January 2026, the company reported a total income of Rs 41.94 crore and a PAT of Rs 5.74 crore.

Utilization of Proceeds

The company intends to utilize the fresh capital to bolster its manufacturing capabilities. Approximately Rs 15.96 crore is earmarked for capital expenditure to set up a new manufacturing unit at the Medical Device Park under the Yamuna Expressway Industrial Development Authority in Gautam Buddha Nagar, Uttar Pradesh. An additional Rs 8.25 crore will be deployed to meet working capital requirements.

Key Takeaways